BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen S, Huang Z, Liang Y, Zhao X, Aobuliksimu X, Wang B, He Y, Kang Y, Huang H, Li Q, Yao Y, Lu X, Qian X, Xie X, Liu J, Liu Y. Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort. ESC Heart Fail 2022. [PMID: 35437939 DOI: 10.1002/ehf2.13921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lou Y, Hu T, Huang J. Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China. Am J Cardiovasc Drugs 2022. [PMID: 36207658 DOI: 10.1007/s40256-022-00550-9] [Reference Citation Analysis]
2 Lou Y, Yu Y, Liu J, Huang J. Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials. Front Public Health 2022;10:959139. [DOI: 10.3389/fpubh.2022.959139] [Reference Citation Analysis]